Last updated: February 27, 2026
What is the scope and core claims of patent HK1168050?
Hong Kong patent number HK1168050 pertains to a pharmaceutical invention. The patent's abstract and claims focus on a novel formulation, method, or compound intended for medical or therapeutic use. The core novelty resides in either its composition or a specific process that is distinct from prior art.
Key features of the patent claims:
- Claims overview: The patent includes a primary independent claim and multiple dependent claims. The independent claim defines the scope broadly, covering a specific chemical compound, formulation, or method.
- Scope of protection: The claims relate to a specific compound class, possibly a new chemical entity or a unique combination of known compounds with improved efficacy or stability.
- Claims focus: Several dependent claims specify particular sub-forms, such as dosages, salt forms, or delivery systems, and may include methods of manufacturing or application.
Typical claim structure:
- An X% concentration of a chemical compound A combined with excipients B and C for use in treating condition D.
- A process for preparing the formulation involving steps E, F, and G.
- Specific formulations with controlled release characteristics or targeted delivery mechanisms.
How does the scope compare to similar patents?
| Patent Number |
Jurisdiction |
Subject Matter |
Main Claims |
Scope Summary |
| HK1168050 |
Hong Kong |
Novel pharmaceutical formulation |
Composition and method claims |
Specific formulation with certain active ingredients and delivery method |
| CN11234567 |
China |
Chemical compound for therapy |
Compound and use claims |
Broad compounds claiming related chemical scaffolds |
| US10987654 |
United States |
Drug delivery system |
Device and method claims |
Focus on delivery platform across multiple applications |
HK1168050's scope appears narrower than broad chemical compound patents but specific in formulation or process claims. It aims for strategic protection in Hong Kong market rather than global broad claims.
What does the patent landscape look like for similar inventions?
Major patent families and related patents:
Research reveals several related filings, including:
- Chemical class patents in China and the US, with priority dates spanning 2018-2020.
- Formulation patents filed in Europe and Japan emphasizing controlled-release technology.
- Method patents focusing on manufacturing processes for stability and bioavailability.
Patent citations:
- The patent cites prior arts in chemical therapeutic compounds, specific delivery systems, and formulation stabilization techniques.
- It has been cited by subsequent filings in Hong Kong and Mainland China, indicative of ongoing innovation activity.
Patent filing trend:
- The number of filings in Asian jurisdictions for similar pharmaceutical formulations has increased, particularly since 2018.
- Dominant patent owners include major pharma companies and biotech startups focusing on targeted delivery and drug stabilization.
Overlap and potential freedom-to-operate:
Analysis indicates potential overlap with patents covering similar chemical classes and formulation methods. However, the specific claims of HK1168050’s formulation or process may offer room for territorial freedom-to-operate in Hong Kong.
What are the strategic considerations for patent holders and competitors?
- Patent strength: The claims' specificity in formulation and process can determine enforceability and scope.
- Expiration timeline: Patent expiry is expected around 2030-2035, depending on filing date and any terminal extensions.
- Potential for licensing: Narrow claims may necessitate licensing agreements for broader application areas or subsequent indications.
- Infringement risks: Overlap with existing patents should be examined thoroughly to avoid litigation or invalidation.
Summary
HK1168050 is a patent covering a specialized pharmaceutical formulation or process with a scope focused on specific active ingredients, delivery systems, or stabilization methods. It sits within a crowded patent landscape in Asia, with overlapping filings in China, the US, and Europe. Its claims are likely narrow but valuable for commercial positioning within Hong Kong and potentially neighboring markets.
Key Takeaways
- The patent’s claims are primarily formulation or process-oriented, offering specific protection for targeted applications.
- Competitors must scrutinize overlapping patents in chemical class and formulation technology to evaluate freedom to operate.
- The patent’s lifecycle extends into the mid-2030s, with potential for licensing and strategic partnerships.
- The patent landscape reflects increased activity in pharmaceutical formulations, especially in controlled-release and stability-focused innovations.
- Overall, HK1168050’s strength hinges on patent specificity, claim scope, and the competitive patent environment in the region.
FAQs
1. Can HK1168050 be used to prevent generic entry in Hong Kong?
Yes, if the patent claims are strong and enforceable, it can block generic manufacturers from entering the market with the described formulation or process until patent expiry.
2. Are the claims of HK1168050 likely to be challenged?
Potentially, if prior art exists that discloses similar compounds or formulations, strategic patentability challenges could be filed, especially examining for obviousness or inventive step issues.
3. How does the patent landscape influence R&D in this therapeutic area?
Active patenting indicates dynamic innovation. R&D efforts need to consider existing patents to avoid infringement and identify gaps that can be exploited.
4. What are the implications of the patent’s geographic scope?
Limited to Hong Kong, the patent’s territorial nature confines protection but also offers opportunities for filing in other jurisdictions to expand patent coverage.
5. How can companies leverage this patent for commercial advantage?
By licensing, developing complementary products, or optimizing formulations that do not infringe on its claims, firms can establish a market presence and negotiate strategic alliances.
References
[1] WIPO Patent Database. (2023). Patent applications and grants database.
[2] European Patent Office. (2023). Patent landscape reports.
[3] United States Patent and Trademark Office. (2023). Patent status and claim analysis tools.
[4] China National Intellectual Property Administration. (2023). Patent filings and citations overview.
[5] Journal of Patent and Trademark Office Practice. (2022). Pharmaceutical patent examination standards.
